Boehringer Ingelheim Office Hours
Boehringer Ingelheim Office Hours
Search
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund
Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy
dose adjustments reduce the frequency and intensity of adverse
Top-line Phase II Data for treatment of MASH
Boehringer Ingelheim and Zealand Pharma announced top-line Phase II data for treatment of metabolic dysfuntion-associated steatohepatitis (MASH).
Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC
Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC
Boehringer Ingelheim, Sodexo and Food Rescue US Collaborate to Nourish Fairfield County’s Food Insecure in Response to the COVID-19 Crisis
Boehringer Ingelheim, Sodexo and Food Rescue US Collaborate to Nourish Fairfield County’s Food Insecure in Response to the COVID-19 Crisis
Clinical trials deliver medical breakthroughs – but how do they happen?
Clinical trials deliver medical breakthroughs – but how do they happen? Prof. Dr Martina Brueckmann talks about her role getting new drugs to trial.
Liliana Montano
Liliana Montano works as a scientist within the Global Innovation and Alliance Management and talks about her journey at Boehringer Ingelheim.
Brigitte Fuhr
Brigitte Fuhr, Head of Central Data Science, is working on a global program that will transform our ability to develop breakthrough treatments.
Matthias Muenks
Matthias Muenks, Global Engineering Process and Data Manager at Boehringer Ingelheim, speaks about the pharmaceutical company’s innovation and culture.
BI initiates Study of Sequencing in EGFR Lung Cancer | BI US
Boehringer Ingelheim has initiated a real-world study to assess the impact of sequential therapy in patients with EGFR mutation-positive advanced NSCLC.
Cookie Statement
Cookie Statement
Foot & Mouth Disease: Know the Facts | Boehringer Ingelheim US
Click here to read more on how the US is planning to create a vaccine bank to guard against and prevent foot-and-mouth disease in livestock across the USA.
Innovation in CardioMetabolic Disease Research
Innovation in CardioMetabolic Disease Research
Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC
Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC
Boehringer Ingelheim expands free telemedicine platform to connect veterinarians and pet owners at a time of social distancing
Boehringer Ingelheim expands free telemedicine platform to connect veterinarians and pet owners at a time of social distancing
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
How Simulation is Changing the Game in Biotherapeutic Drug Development
How Simulation is Changing the Game in Biotherapeutic Drug Development
Oncology & Cancer Immunology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Cooking Up Change: Boehringer Cares Foundation and World Central Kitchen’s Recipe for Fighting Hunger
Our Boehringer Cares team has partnered with World Central Kitchen who aim to address the critical issue of global food insecurity.
Tereza Urbankova
Tereza Urbankova, a senior manager in Global Media Relations, says that the teams feel really tight knit and always supporting each other.
Rafal Rybicki
Rafał Rybicki, Head of Legal and Compliance Services in the Global Business Services (GBS) Center in Wroclaw, reflects on his first year with the company.
Why cancer care is personal for us
At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
Currency-adjusted net sales rose by 9.7 percent to 13.5 billion USD.